Physician profile
Douglas C Walker
NPI 1821095142
$3,832.63
in general payments reported to CMS, 2019-2025
40 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $670 · 2021: $881 · 2022: $554 · 2023: $526 · 2024: $365 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $554.54 | 2019-2024 | Xarelto |
| Abbvie INC. | $414.27 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $274.34 | 2019-2024 | Airsupra, Breztri |
| Amarin Pharma, INC. | $248.44 | 2019-2022 | |
| Merz North America, INC. | $238.25 | 2021 | |
| Lilly USA, LLC | $169.45 | 2019-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $148.84 | 2019-2024 | |
| Amgen INC. | $145.18 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $130.89 | 2019-2023 | |
| Abbott Laboratories | $115.50 | 2021-2023 | Id Now Instrument |
| E.R. Squibb & Sons, L.L.C. | $75.16 | 2019-2022 | |
| Novo Nordisk INC | $69.41 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.60 | 2019-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $48.99 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.